The ubiquitin proteasome system (UPS) is the main system for controlled protein degradation and a key regulator of fundamental cellular processes. The dependency of cancer cells on a functioning UPS has made this an attractive target for development of drugs that show selectivity for tumor cells. Deubiquitinases (DUBs, ubiquitin isopeptidases) are components of the UPS that catalyze the removal of ubiquitin moieties from target proteins or polyubiquitin chains, resulting in altered signaling or changes in protein stability. A number of DUBs regulate processes associated with cell proliferation and apoptosis, and as such represent candidate targets for cancer therapeutics. The majority of DUBs are cysteine proteases and are likely to be more "druggable" than E3 ligases. Cysteine residues in the active sites of DUBs are expected to be reactive to various electrophiles. Various compounds containing α,β-unsaturated ketones have indeed been demonstrated to inhibit cellular DUB activity. Inhibition of proteasomal cysteine DUB enzymes (i.e. USP14 and UCHL5) can be predicted to be particularly cytotoxic to cancer cells as it leads to blocking of proteasome function and accumulation of proteasomal substrates. We here provide an overall review of DUBs relevant to cancer and of various small molecules which have been demonstrated to inhibit DUB activity.
Introduction
Proteins are vital to the structure and function of cells, and as such the regulated control of protein turnover is a fundamental aspect of cellular metabolism.~30% of newly synthesized proteins in mammalian cells are rapidly degraded with a half-life of b10 min (Schubert et al., 2000) . Such a high rate of protein turnover requires a specialized system for the controlled and selective degradation of unwanted proteins. The ubiquitin-proteasome system (UPS) has emerged as a key regulator of protein function and stability. At its most simple level the UPS is composed of a tagging factor in the form of the small molecule ubiquitin which marks unwanted or damaged proteins for degradation, and the proteasome, a large molecular shredder that breaks down proteins into smaller peptides for use in other anabolic processes. More than 80% of cellular proteins are degraded by the UPS, high-lighting the importance of this pathway in the regulation of multiple cellular processes (Rock et al., 1994) . The multifaceted role of the UPS includes the degradation of misfolded and damaged proteins, cell cycle regulators, oncogene and tumor suppressor proteins, as well as the regulation of antigen processing and control of transcription factor activity (Coux et al., 1996; Hershko & Ciechanover, 1998) . Considering the diversity of UPS substrates it is no surprise that this pathway has been implicated in the pathogenesis of many human diseases such as neurodegenerative disorders, viral diseases and cancer (Ciechanover et al., 2000) .
The process of ubiquitination is a multi-step process ultimately leading to the covalent modification of a protein substrate with the small molecule ubiquitin. Ubiquitin is a highly conserved 76 amino acid protein that undergoes covalent attachment via an isopeptide bond between the carboxy glycine residue (G76) of ubiquitin to the ε-amino groups of lysine residues in target proteins. The process of ubiquitination is dependent on the consecutive activity of three distinct enzymes, Ub-activating (E1), Ub-conjugating (E2) and Ub-ligating (E3) (Fig. 1) . In the first step, ubiquitin is activated by the E1 enzyme in the presence of ATP, forming a thioester bond between the carboxy-terminal glycine residue of ubiquitin and the active site cysteine of the E1 enzyme. Once activated, ubiquitin is transferred from E1 to a cysteine residue of one of the 30-40 E2 ubiquitin carrier proteins. Substrate specificity is conferred by E3 ligases, which bind target substrates and co-ordinate the covalent attachment of ubiquitin. Two distinct families of E3 ligases exist, the HECT domain family that receives ubiquitin from the E2 ligase forming an ubiquitin-E3 intermediate, and the RING finger family of E3 ligases that form a molecular bridge between the E2 ligase and target proteins. There are N500 E3 ligases in cells, making them the main specificity factor in the UPS (Hershko et al., 1983; Voges et al., 1999; Pickart & Eddins, 2004) .
There are three different classes of ubiquitination: i) monoubiquitination where a single ubiquitin is attached, ii) multiubiquitination or poly-monoubiquitination where several single ubiquitin moieties are attached, and iii) poly-ubiquitination where substrates are tagged with polyubiquitin chains (Jentsch & Schlenker, 1995; Hicke, 2001; Di Fiore et al., 2003; Haglund et al., 2003; Haglund & Dikic, 2005; Ye & Rape, 2009; Lander et al., 2012) . In addition to the three different classes of ubiquitination, a ubiquitin code exists whereby the type of linkages between ubiquitin monomers determines function. Ubiquitin contains seven lysine residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63), any of which can serve as sites for the covalent attachment of other ubiquitin molecules. The nature of the linkages within the polyubiquitin chain has consequences in determining the fate of the conjoined protein. In general, proteins tagged with Lys48-linked polyubiquitin chains are destined for proteasomal degradation (Chau et al., 1989; Hershko & Ciechanover, 1998) , whereas modifications involving Lys63-linked chains are more typically associated with nonproteasomal roles such as DNA repair, DNA replication and signal transduction (Haglund & Dikic, 2005) . Other linkage types are generally less well characterized, although reports have shown that polyubiquitin chains linked through Lys6, Lys11, Lys27, Lys29, or Lys33 can target proteins for proteasome-mediated degradation ). Even Lys63 chains, which are more traditionally implicated in signaling, can target the attached protein to the proteasome for degradation (Saeki et al., 2009) .
The process of ubiquitination is highly dynamic and can be reversed by the action of specialized enzymes known as deubiquitinases (DUBs) . DUBs oppose the action of the E3 ligases by cleaving the isopeptide bond between lysine residues on target proteins and the C-terminal glycine of ubiquitin. Analysis of the human genome shows the presence of~80 Proteins are targeted for degradation by the addition of ubiquitin chains to lysine residues by a process that involves three enzymes. Ubiquitin is activated by a ubiquitin-activating enzyme (known as E1) and transferred to a cysteine residue of a ubiquitin carrier protein (known as E2). E3 ligases bind target substrates and co-ordinate the covalent attachment of ubiquitin. The existence of a large number (N500) of E3 ligases makes them the main specificity factor in the UPS. Target proteins may be monoubiquitinated or, as in this example, polyubiquitinated. A target protein must be tagged with at least four ubiquitin monomers (forming a polyubiquitin chain) to be recognized by the proteasome.
functional DUBs (Komander et al., 2009 ), accounting for a major fraction of the~460 functional proteases (Fortelny et al., 2014) . Based on active site homology, DUBs can be divided into six classes: ubiquitin-specific proteases (USPs), ubiquitin carboxy-terminal hydrolases (UCHs), ovarian-tumor proteases (OTUs), Machado-Joseph disease protein domain proteases, JAMM/MPN domain-associated metallopeptidases (JAMMs) and monocyte chemotactic protein-induced protein (MCPIP) (Fraile et al., 2012; Fortelny et al., 2014) . Of these DUBs, the USP class is the most numerous, due to a rapid diversification during evolution, possibly in concert with the diversification of E3 ligases (Semple et al., 2003) . This process has presumably led to an increased capacity for specific ubiquitination and deubiquitination events, similar to that observed for protein phosphorylation, where both kinases and phosphatases are important for regulatory circuits. A more detailed overview of different DUBs is given below.
The proteasome
The 26S proteasome is a large ATP-dependent protease complex found in the cytosol and the nucleus of eukaryotic cells (Tanaka et al., 1983; Bochtler et al., 1999; Goldberg, 2003) . The 26S proteasome consists of~50 different subunits with a combined molecular weight of 2.5 MDa (Fig. 2) . The 26S proteasome is arranged into two subcomplexes: a catalytic 20S core particle (CP) capped by one or two 19S regulatory particle(s) (19S RP).
The 20S core particle
The eukaryotic 20S CP is a~730 kDa cylinder-shaped multimeric complex composed of two heptameric inner β-rings capped by two heptameric α-subunits (Groll et al., 1997; Unno et al., 2002) . The outer α-rings provide attachment sites for the 19S RP as well as forming a 13 Å molecular gate to control substrate access to the catalytic chamber. The proteolytic activity of the 20S CP is mediated by the β1, β2 and β5 subunits, which contain catalytically active threonine residues at their N termini. The catalytic β-subunits are classified based on substrate preference with the β1-subunits associated with caspase-like activity, β2-subunits with trypsin-like activity, and β5-subunits with chymotrypsin-like activity. Substrate proteins are degraded into oligopeptides ranging in length from 3 to 15 amino-acid residues, which are subsequently hydrolyzed by cytosolic peptidases into free amino acids Zwickl et al., 1992; Lowe et al., 1995; Groll et al., 1997) . Alternatively, proteasome-processed oligopeptides may be taken up by the TAP1 complex and loaded onto histocompatibility complex (MHC) class I molecules for presentation to the immune system (Saeki & Tanaka, 2012) .
The 19S regulatory particle
The 19S RP is a~930 kDa complex consisting of at least 19 different subunits that can be further divided into lid and base sub-complexes (Glickman et al., 1998; Lander et al., 2012) (Fig. 2) . The base of the 19S RP is composed of ten subunits, six of which are related AAA + ATPases (Rpt1-Rpt6) that form a hetero-hexameric ring (Tomko et al., 2010) . The ATPase ring plays an important role in the opening of the gated channel to the 20S CP as well as utilizing the hydrolysis of ATP to drive the unwinding and translocation of ubiquitinated proteins through the narrow pore into the 20S CP for degradation (Smith et al., 2007; Martin et al., 2008; Rabl et al., 2008; Zhang et al., 2009; Maillard et al., 2011; Erales et al., 2012) . The other four base subunits are the scaffolding proteins Rpn1 and Rpn2 and the ubiquitin receptors S5a/Rpn10 and Rpn13. These receptors display preferences for the type of ubiquitin complexes captured. Rpn10 contains two C-terminal ubiquitin-interacting motifs (UIMs) that cooperate to bind polyubiquitin chains (Deveraux et al., 1995; Elsasser et al., 2004; Finley, 2009) , whereas, Rpn13 binds to Lys48-linked di-ubiquitin with high affinity. In addition, three nonconstitutive ubiquitin receptors, Rad23, Dsk2 and Ddi1, also associate with the proteasome and modulate the binding of ubiquitinated cargo. The extrinsic ubiquitin receptors contain ubiquitin-like (UBL) domains that bind to the 19S RP subunits Rpn1, Rpn10 and Rpn13 and ubiquitin-associated (UBA) domain that bind polyubiquitinated substrates (Hartmann-Petersen & Gordon, 2004) . In addition to binding ubiquitin, Rpn13 serves also as a receptor for the DUBs Uch37/UCHL5, thus providing a link between chain recognition and disassembly (Husnjak et al., 2008) . In order to facilitate the degradation of proteasome-targeted substrates, specialized proteasome-associated DUBs function to remove bulky ubiquitin moieties that may otherwise impede entry to the 20S CP (Verma et al., 2002; Yao & Cohen, 2002) . This process also leads to recycling of free ubiquitin for further use by the UPS (Fig. 3) . Such DUB activity also provides a care taker function by clearing of substrate-free polyubiquitin chains that may otherwise become stuck to the proteasome.
Three DUBs are associated with the proteasome: Rpn11/POH1, Ubp6/USP14 and Uch37/UCHL5 (yeast/human nomenclature Fig. 2 . Structure of the proteasome in higher eukaryotes. The various components of the 20S core particle (CP) and 19S regulatory particles (RP) are shown. The 20S proteasome contains 14 different subunits overall (α1-α7 and β1-β7) which show molecular masses between 20 and 30 kDa, totalling a molecular weight of~700 kDa. The α-rings are responsible for the regulation of substrate entrance and for recognition and binding of the substrate whereas the catalytic centers are located in the β-rings. The β1 subunit shows a peptidyl-glutamyl-peptide hydrolyzing activity ("caspase-like" activity); the β2 subunit cleaves after basic amino acids ("trypsin-like" activity); the β5 subunit cleaves after neutral amino acids ("chymotrypsin-like" activity). The 19S regulatory particle consists of two main structures: a ring-shaped base and a lid that recognizes and binds polyubiquitinated proteins. The base ring contains at least 10 different subunits (Rpt1-Rpt6, Rpn1, Rpn2, Rpn10 and Rpn13). The lid contains 9 subunits (Rpn3, Rpn5-Rpn9, Rpn11, Rpn12 and Rpn15). The Rpt-subunits display ATPase activity (Rpt: regulatory particle ATPase), Rpnsubunits do not (Rpn: regulatory particle non-ATPase). Rpn11 (POH1) is a metalloprotease with DUB activity.
POH1 is a metalloprotease which belongs to the JAMM domain family and is an integral part of the 19S RP lid. Uch37/UCHL5 and Ubp6/ USP14 are cysteine proteases and members of the ubiquitin Cterminal hydrolase (UCH) and ubiquitin specific protease (USP) families, respectively. Both UCHL5 and USP14 are physically associated with the base complex of the 19S RP, and their DUB activity is stimulated upon proteasome incorporation. Rpn11/POH1 is essential for viability in yeast and metazoan cells (Rinaldi et al., 1998; Gallery et al., 2007) . In addition to its function as a DUB, Rpn11/POH1 is essential for 26S proteasome structure and activity (Lundgren et al., 2003; Gallery et al., 2007) . Rpn11/POH1 contains a JAMM/MPN + motif sequence containing two histidine residues and an aspartic residue coordinating a zinc ion, which is important for proteolytic activity (Maytal-Kivity et al., 2002; Ambroggio et al., 2004) . The activity of Rpn11/POH1 is thought to be delayed until the proteasome is committed to degrade the substrate (Verma et al., 2002; Yao & Cohen, 2002; Lee et al., 2011) . Rpn11/POH1 cleaves the proximal end of the polyubiquitin chain from the substrate, resulting in the release of a free ubiquitin chain. To allow cleavage without disengaging from the receptor, an ubiquitin chain must be long enough to span the distance between the receptor and the DUB. At least four ubiquitin moieties are necessary to span the distance between receptors Rpn10 or Rpn13 and Rpn11/POH1 (Verma et al., 2002; Yao & Cohen, 2002; Lander et al., 2012) . The DUB USP14 is important for ubiquitin recycling. This DUB is not a constitutive proteasome subunit and reversibly associates with the Rpn1 subunit of the 19S RP base. Association of USP14 with the proteasome results in enhanced DUB activity (~1000 fold) when compared to unbound enzyme (Borodovsky et al., 2001 ). The USP14 protein contains an N-terminal 9-kDa UBL domain and a 45-kDa catalytic domain. Cys114, His435, and Asp451 form a catalytic triad in the active site of free USP14, and the catalytic mechanism of USP14 appears to parallel that of the papain family of cysteine proteases (Hu et al., 2005) . USP14 is structurally related to USP7 (HAUSP). An important difference is that the catalytic site is misaligned in free USP7 and is properly formed after binding of ubiquitin (Hu et al., 2005) . The ubiquitin binding pocket of Ubp6/USP14 is blocked by two loops which must be removed in order to catalyze deubiquitination (Hu et al., 2005) . It has been proposed that the binding of Ubp6/USP14 to the base of the 19S RP induces a conformational change in the two loops to make the active site for ubiquitin accessible (Hu et al., 2005) . Lys48-linked polyubiquitin chains are the preferable substrates for Ubp6/USP14 and are cleaved from their distal tips (Hu et al., 2005; Hanna et al., 2006) . Ubp6/USP14 was shown to inhibit proteasome activity by delaying the breakdown of proteins by the proteasome (Lee et al., 2010 (Lee et al., , 2011 . It is suggested that Ubp6/USP14 prevents deubiquitination of the proteasome substrate by Rpn11/POH1. This allows the substrate to be docked at the proteasome for a longer time, thus resulting in more extensive trimming of ubiquitin chains, which reduces substrate binding affinity to the proteasome and favors release back to the cytosol (Hanna et al., 2006; Lee et al., 2010) . The Saccaromyces cerevisiae orthologue of USP14, Ubp6, is nonessential for cell viability (Guterman & Glickman, 2004) , although it appears important for cell survival following metabolic stress. In mammalian cells, knock-down of USP14 had no detectable effect on proteasome structure or the accumulation of polyubiquitin (Koulich et al., 2008) . The small molecule USP14 inhibitor IU1 was shown to reduce chain trimming and stimulate proteasome degradation, indicating the ability of USP14 to inhibit the proteasome through its deubiquitinating activity (Lee et al., 2010) . Although nonessential for cell survival, USP14 does appear to be important for normal neuronal development. USP14 mutant mice (ax J /ax J mice) develop severe tremors, hindlimb paralysis and die by 6-10 weeks of age (Wilson et al., 2002) . In these mice, the levels of monomeric ubiquitin are decreased at synapses, suggesting that decreased recycling of ubiquitin at synapses cannot be fully compensated by axonal transport of newly synthesized ubiquitin (Chen et al., 2009 ). These different observations could be explained by USP14 being required for ubiquitin turnover in particular cellular compartments. Ubp6/USP14 is also involved in the regulation of gate opening of the 20S core particle. Binding of polyubiquitin conjugates to the 26S proteasome increases peptide hydrolysis by increasing 20S gate opening. Polyubiquitin conjugates interact with Ubp6/USP14 and in this way stimulate gate opening, enabling the substrate to be degraded (Peth et al., 2009) . Efficient proteolysis is a multistep process and Ubp6/ USP14 is clearly critical in integrating these multiple reactions. While helping to remove the ubiquitin chain, it also enhances gate opening by the ATPase ring in order to ensure efficient destruction of the substrate. It has been found that most of the cellular Ubp6/USP14 is not associated with the proteasome, indicating that it may be involved in other cellular processes (Koulich et al., 2008) .
The Uch37/UCHL5 deubiquitinase is well conserved from fungi to humans (Yao et al., 2006 ). An orthologue of human Uch37 has not been found in S. cerevisiae. The orthologue in Saccaromyces pombe, Uch2, is nonessential for viability (Li et al., 2000) . Uch37/UCHL5 appears to be reversibly associates with the proteasome (Hamazaki et al., 2006; Jorgensen et al., 2006; Qiu et al., 2006; Yao et al., 2006) . In contrast to Rpn11/POH1, Uch37/UCHL5 is not important for the activity or the structure of the 26S proteasome. The isopeptidase enzyme activity of Uch37/UCHL5 is enhanced after binding of the protein to the 26S proteasome (Koulich et al., 2008) via the Rpn13/Admr1 receptor in the 19S RP base complex. The UCH-domain contains an active-site crossover loop which must be displaced to allow substrate entry. This autoinhibitory function is reversed by binding of Uch37/UCHL5 to Rpn13/ Admr1 of the proteasome (Hamazaki et al., 2006; Qiu et al., 2006; Yao et al., 2006) . Similar to Ubp6/USP14, Uch37/UCHL5 removes ubiquitin from the distal tip of polyubiquitin chains. While Ubp6/USP14 is able to release di-and tri-ubiquitin from chains, Uch37/UCHL5 releases only monoubiquitin (Lam et al., 1997; Hanna et al., 2006) . Uch37/ UCHL5 cleaves both Lys48-and Lys63-linked polyubiquitin chains (Jacobson et al., 2009) . It is believed that Uch37/UCHL5 suppresses protein degradation by shortening the chains of inappropriately or poorly modified substrates (Lam et al., 1997; Koulich et al., 2008) . In contrast, a recent study has suggested that Uch37/UCHL5 promotes the degradation of specific proteasome substrates, nitric oxide synthase and IκB-α (Mazumdar et al., 2010) . Thus, Uch37/UCHL5 appears to suppress the degradation of some substrates while promoting the degradation of others.
The exact difference in catalytic function between Ubp6/USP14 and Uch37/UCHL5 is not clear. Double knockdown of Ubp6/USP14 and Uch37/UCHL5 results in inhibition of cell growth, decreased protein degradation, and accumulation of polyubiquitinated proteins, a phenotype similar to that observed after knock-down of Rpn11/POH1 (Lundgren et al., 2003) . RNAi-mediated down-regulation of either DUB alone creates a complete opposite phenotype where cell growth is not affected and reduced levels of polyubiquitinated proteins are observed, indicating that each enzyme could compensate for loss of function of the other (Koulich et al., 2008) .
DUBs as drug targets for cancer therapeutics
In the following section we will discuss parts of the literature relevant to the role of DUBs in cancer, as well as the therapeutic potential of targeting DUBs as a treatment option for cancer (see also excellent reviews by Nijman et al. (2005b) , Hussain et al. (2009 ), Komander et al. (2009 ), Sacco et al. (2010 , Ramakrishna et al. (2011) , and Eletr and Wilkinson (2014) ). Several DUBs have been described to play essential roles in the regulation of numerous cellular processes, particularly those frequently altered in tumorigenesis, e.g. cell cycle control, cell signaling and apoptosis. We will briefly describe these DUBs and give examples of their roles in the etiology of cancer. Several functional screens have been performed to identify DUBs involved in complex processes such as DNA repair, cell cycle regulation and receptor signaling. These studies have generally found that multiple DUBs are involved in these processes, suggesting considerable redundancy in DUB-regulated processes.
Examples of cellular processes involving DUBs
The process of ubiquitination has been shown to play essential roles for DNA-repair and DNA-damage response pathways. These pathways typically involve the mono-ubiquitination of key DNA-repair proteins that have important regulatory functions in processes such as homologous recombination and trans-lesion DNA synthesis (Huang & D'Andrea, 2006) . One of the most studied DUBs in DNA repair is USP1, a negative regulator of FANCD2 mono-ubiquitination (Nijman et al., 2005a) . USP1 also deubiquitinates PCNA (proliferating cell nuclear antigen), an important component of the trans-lesions synthesis (TLS) repair pathway . USP28 is required for the stabilization of Chk2 and 53BP1 following DNA damage (Zhang et al., 2006) and loss of USP28 is predicted to increase the susceptibility to ionizing radiation. The DUB BRCC36 is a constituent of the BRCC (BRCA1 and BRCA2 Containing Complex) (Dong et al., 2003) . This complex is required for the response to ionizing radiation and for maintaining a G2 DNA checkpoint. BRCC36 counteracts the ubiquitination of H2AX and H2A to terminate the double-strand break response (Sobhian et al., 2007) .
Ubiquitination of H2B leads to a more open chromatin structure, enhancing the accessibility for transcription factors and DNA repair proteins. The ubiquitination of H2B is regulated by the E3 ligase action of the RNF20-RNF40 complex and the opposing activity by a number of DUBs, including USP7, USP22 and USP44. Many advanced cancers typically display low levels of ubiquitinated H2B compared to normal or early stage tumors, suggesting a role for these enzymes in disease progression. Components of the UPS regulating H2B ubiquitination status may represent new therapeutic targets for the treatment of cancer (Cole et al., 2014) . Consistent with this concept, compounds that inhibit the UPS have been shown to act in synergy with clinically used DNA damaging drugs.
As recently reviewed (Ramakrishna et al., 2011) , a number of DUBs have been shown to regulate the process of programmed cell death (apoptosis), either positively or negatively. These authors listed 14 DUBs with apoptosis promoting activity, including USP7, USP9x, USP28 and CYLD. Only 3 DUBs were regarded as negative regulators of apoptosis (A20, USP18 and UCHL3). From a perspective of small molecule inhibitors as cancer therapeutics, the latter category is of course of immediate interest.
The UPS may be particularly important for the interferon response. The ubiquitin-like (Ubl) protein ISG15 (interferon-stimulated gene product of 15 kDa) shows significant homology to ubiquitin and is covalently attached to target proteins in a similar manner (Haas et al., 1987; Loeb & Haas, 1992) . A number of DUBs have been shown to have important roles in interferon signaling, including OTUD5 (DUBA) (Kayagaki et al., 2007) , OTUB1/OTUB2 , USP3 (Cui et al., 2014) , USP17 and USP25 (Zhong et al., 2013) . Conversely, viruses have been shown to encode DUB enzyme activities that counteract interferon induction as a means of escaping innate immune responses van Kasteren et al., 2012) .
The UPS is involved at multiple levels of the Met receptor tyrosine kinase pathway (Buus et al., 2009) Proteolysis by the proteasome. Polyubiquitinated proteins are recognized and bind to the 19S regulatory particle by an ATP-dependent mechanism. Substrates must be partially unfolded before they enter into the catalytic chamber of the 20S core particle. Substrate unfolding is an energy-dependent process. The polyubiquitin chain is removed by proteasomeassociated DUBs (deubiquitinases, ubiquitin isopeptidases) prior to translocation of the substrate into the 20S particle. Proteolysis occurs within the central chamber, generally resulting in~7-9 amino acid peptides.
identified to be required for hepatocyte growth factor (HGF)-dependent scattering response of A549 cells, including USP3, USP30, USP33, USP47 and ATXN3L (Buus et al., 2009) .
A number of DUBs are involved in direct or indirect regulation of the stability of the p53 tumor suppressor protein: USP2, USP7, USP10, USP22, USP42 and OTUD5. A large body of evidence points to mutant p53 in tumors having gain-of-function and decreasing the stability of mutant p53 may be a viable therapeutic strategy. Similar to wild-type p53, mutant p53 is regulated by Mdm2 (Terzian et al., 2008) .
Genetic alterations affecting DUB genes are found in human tumors
Mutations in genes encoding DUBs have been detected in human cancers, illuminating the importance of DUBs in processes of direct importance for cancer cell biology. Germline mutations in the CYLD gene were identified in kindreds with familial cylindromatosis and sporadic cylindromas (Bignell et al., 2000) and also in patients with BrookeSpiegler syndrome and familial trichoepithelioma (Poblete Gutierrez et al., 2002) . These are autosomal dominant inherited diseases associated with the development of multiple skin tumors of the head and neck. Mutations are thought to affect the catalytic activity of CYLD enzyme. Aberrant USP6 expression, resulting from gene translocation, has been found to be causative in most instances of aneurysmal bone cysts (Oliveira et al., 2004) , locally aggressive bone lesions that occur during the first two decades of life (Rapp et al., 2012) . The translocation, t(16;17)(q22;p13), fuses the promoter for the osteoblast cadherin 11 gene to the full-length USP6 gene resulting in upregulated USP6 transcription. A20 (TNFAIP3/tumor necrosis factor alpha-induced protein 3) is required to terminate NFκB signaling in response to tumor necrosis factor. Inactivating A20 mutations were reported to be frequently occurring in cases of marginal zone lymphoma (Novak et al., 2009 ). Furthermore, an almost complete loss of A20 mRNA expression has been observed in cases of Non-Hodgkin's Lymphoma (Durkop et al., 2003) . Various types of genetic alterations have been found in the gene encoding the BAP1 deubiquitinase in various diseases, including lung and breast tumors, clear cell renal cell carcinomas and malignant pleural mesotheliomas (Buchhagen et al., 1994; Jensen et al., 1998; Jensen & Rauscher, 1999; Bott et al., 2011; Pena-Llopis et al., 2012) . Mutations occurring in BAP1 were reported to lead to loss of deubiquitinating activity (Ventii et al., 2008) . Finally, the USP42 gene is a fusion partner in the (7;21)(p22;q22) translocation in acute myeloid leukemia (AML) (Paulsson et al., 2006) .
Association of DUBs with processes relevant to cancer
A short overview of DUB activities relevant to cancer is presented below. We have focussed on mechanisms with potential translational potential in cancer. The field is growing rapidly, and due to space restrictions the overview is not complete.
USP1 is involved in the DNA damage response (Nijman et al., 2005a) . USP1 regulates DNA repair and the Fanconi anemia pathway through its association with UAF (USP1 associated factor 1; WDR48) and through its deubiquitination of two critical DNA repair proteins, FANCD2-Ub and PCNA-Ub. USP1 is activated by complex formation with UAF1 (USP1 associated factor 1; WDR48). USP1 deubiquitinates the DNA replication processivity factor, PCNA, as a safeguard against error-prone translesion synthesis of DNA (replication at sites of DNA damage). Ultraviolet (UV) irradiation inactivates USP1 through an autocleavage event, thus enabling monoubiquitinated PCNA to accumulate and to activate translesion DNA synthesis . UAF1-deficient cells have severe defects in homologous recombination (HR)-mediated double-strand break (DSB) repair and are hypersensitive to DNA damaging agents such as camptothecin (Murai et al., 2011) .
USP2 and its different isoforms have been extensively studied by cancer biologists. USP2a is known to associate with Mdm2 and MdmX and has the capacity to deubiquitinate these proteins (Stevenson et al., 2007; . In distinction to USP7/HAUSP, Usp2a does not appear to bind to p53. Overexpression of USP2a leads to increased cellular levels of Mdm2/MdmX and degradation of p53 (Fig. 4) . As expected, suppression of endogenous USP2a leads to destabilization of Mdm2 and accumulation of p53 protein. Usp2a has also been shown to interact with and deubiquitinate Aurora-A (Shi et al., 2011) . The Aurora-A protein is localized to centrosomes and is essential for centrosome duplication (Meraldi et al., 2004) . Knockdown of USP2a leads to reduced protein levels of Aurora-A and abnormal mitosis. Further studies have shown that Usp2a targets cyclin A1 (Kim et al., 2012) and cyclin D (Shan et al., 2009 ), leading to increases in the expression of this protein and enhancement of cell proliferation. Fatty acid synthase is known to be overexpressed in many epithelial tumors and important for cell survival (Dhanasekaran et al., 2001 ) and USP2a has been demonstrated to interact with this enzyme (Graner et al., 2004) . USP2a is androgen-regulated and overexpressed in prostate cancer, and functional inactivation of the DUB has been shown to enhance apoptosis of prostate cancer cells (Graner et al., 2004) . Inhibition of Usp2a may be a general strategy to activate p53 in tumor cells , resulting in the induction of tumor apoptosis, at least under some conditions. For example, siRNA depletion of USP2a induced moderate levels of apoptosis in prostate cancer cell lines after 48 h (Graner et al., 2004) . In contrast to these reports, it has been reported that knock-down of USP2c results in apoptosis, while targeting USP2a does not affect cell survival (Mahul-Mellier et al., 2012) . USP2a is a candidate therapeutic target in oncology, the inhibition of which is expected to lead to decreased cell proliferation (Fig. 4) .
USP5 is commonly referred to as isopeptidase T and is known to show specificity for unanchored polyubiquitin chains (Hadari et al., 1992) . Deletion of the yeast homolog of the USP5 gene (Ubp14) results in accumulation of free ubiquitin chains. It was proposed that isopeptidase T facilitates proper proteasome function by preventing unanchored ubiquitin chains competing for ubiquitin receptors on the 19S proteasome (Amerik et al., 1997) . Suppression of USP5/isopeptidase T has been shown to increase both the levels and transcriptional activity of p53 without altering Mdm2 stability (Dayal et al., 2009 ). The mechanism whereby USP5 knockdown stabilizes p53 is by decreasing its proteasome-mediated degradation. It was proposed that p53 is stabilized due to competition between unanchored polyubiquitin chains and ubiquitinated p53 in cells (Dayal et al., 2009) .
USP7, also referred to as HAUSP, has also been identified as a key regulator of p53 activity (Fig. 4) . p53 levels are predominantly regulated by the E3 ubiquitin ligase Mdm2, leading to low intracellular concentrations during normal homeostasis. USP7 was first identified as Herpes virus-associated cellular factor (HAUSP) (Everett et al., 1997) and later shown to deubiquitinate and stabilize p53 . USP7 can also deubiquitinate and stabilize Mdm2 providing an alternative level of p53 regulation (Cummins et al., 2004; . Polycomb repressive complex 1 (PRC1) is known to monoubiquitinate histone H2A. Both USP7 and USP11 co-purify with human PRC1-type complexes and regulate the ubiquitination of some components of these complexes (Maertens et al., 2010) . Removal of USP7 or USP11 in primary human fibroblasts results in increased expression of the INK4a tumor suppressor and proliferative arrest ("senescence").
USP8/UBPY (the mammalian ortholog of budding yeast Ubp4/Doa4) was described as a DUB that accumulates upon growth stimulation of human fibroblasts (Naviglio et al., 1998) . Down-regulation of USP8/ UBPY prevents fibroblasts from entering S-phase in response to serum stimulation (Naviglio et al., 1998) . USP8 has subsequently been found to be involved in EGFR receptor turnover. Following ligand stimulation, the EGFR is ubiquitinated by the E3 ligase Cbl, resulting in receptor internalization. The internalized receptor is subsequently deubiquitinated by USP8 prior to lysosomal degradation (Alwan et al., 2003; Row et al., 2006; Alwan & van Leeuwen, 2007) .
FLIP S is a suppressor of TRAIL-induced apoptosis. FLIP S stability is controlled by the E3 ubiquitin ligase AIP4 (atrophin-interacting protein 4) (Panner et al., 2010) . The stability of the AIP4 ligase is in its turn regulated by USP8. Interestingly, USP8 levels are regulated by the PTENAkt signaling pathway (Panner et al., 2010) . Increased AKT phosphorylation therefore leads to decreased levels of FLIP S and resistance to TRAIL (Fig. 5) . USP8 is required for stabilization of another E3 ubiquitin ligase, Nrdp1 (Wu et al., 2004a) (Fig. 5) . Nrdp1 is involved in the regulation of steady-state ErbB3 levels by mediating growth factor-independent degradation of this receptor (Diamonti et al., 2002; Qiu & Goldberg, 2002) . Akt-mediated phosphorylation of the USP8 threonine residue T907 has been found to regulate USP8 stability (Cao et al., 2007) . Exposure to ErbB3 ligand (neuregulin-1; NRG1) stabilizes USP8, leading to stabilization of Nrdp1.
USP9x is an X-linked ubiquitin specific protease (also known as FAM; fat facet in mouse). The corresponding Drosophila protein faf (fat Usp2a has also been shown to deubiquitinate Aurora-A (a protein essential for centrosome duplication). Downregulation of USP2a leads to decreased levels of Aurora-A protein and abnormal mitosis (right). Usp2a also deubiquitinates and stabilizes cyclin A1 and cyclin D; inhibition of the DUB leads to decreased levels of these proteins (right). (B) USP7 deubiquitinates both p53 and HDM2. Inhibition of USP7 enzyme activity leads to stabilization of p53 protein.
facet) is required for cellularization in early embryos and for cell-fate determination in the Drosophila eye (Fischer-Vize et al., 1992) . USP9x is an essential component of the TGF-β signaling pathway. The activity of the Smad4 transcription factor is impeded by monoubiquitination of lysine 519, a process which is counteracted by USP9x (Dupont et al., 2009 ). USP9x has also been implicated in the regulation of MAPK pathways. USP9X supports ASK1-mediated signaling by preventing proteasomal degradation of activated ASK1 (Nagai et al., 2009 ). USP9x was recently identified as a tumor suppressor gene for pancreatic ductal preneoplasia using an approach of transposon-mediated insertional mutagenesis (Perez-Mancera et al., 2012) . Low USP9X protein and mRNA expression in human pancreatic ductal tumor was found to correlate with poor patient survival. Finally, USP9x has been shown to stabilize the pro-survival protein MCL1 (Schwickart et al., 2010) . MCL1 is expressed at low levels in most cell types due to rapid turn-over due to the action of ubiquitin ligases, but is expressed at high levels in hematological malignances such as B-cell lymphomas, chronic myeloid leukemia and multiple myeloma. A correlation between USP9x expression . USP8 regulates sensitivity to TRAIL. The stability of the AIP4 E3 ubiquitin ligase (atrophin-interacting protein 4) is regulated by USP8. AIP4 regulates the stability of FLIP S . The protein levels of USP8 levels are under control of the PTEN-Akt signaling pathway (USP8 T907 is phosphorylated by Akt). Since FLIP S is a suppressor of TRAIL-induced apoptosis, the activity level of the PTEN-AKT pathway is a determinant of the degree of TRAIL sensitivity (increased AKT activity leads to increased levels of FLIP S ).
Nucleus Cytoplasm p53 Targets
Genotoxic stress . USP10 regulates p53 localization and stability. USP10 is a mainly cytoplasmic DUB which is phosphorylated by ATM (Ataxia telangiectasia mutated) after DNA damage. Phosphorylated USP10 translocates to the nucleus where it deubiquitinates p53 and reverses Mdm2-induced p53 nuclear export and degradation. Increased USP10 expression in p53 mutant cancer cells promotes cell proliferation and downregulation of USP10 inhibits cancer cell growth. Adapted from Yuan et al. (2010) . and MCL1 levels was reported in human follicular lymphomas and diffuse large B-cell lymphomas (Schwickart et al., 2010) .
USP10 is a mainly cytoplasmic DUB which deubiquitinates p53 and reverses Mdm2-induced p53 nuclear export and degradation (Fig. 6) (Yuan et al., 2010) . USP10 is stabilized after DNA damage and translocates to the nucleus to activate p53. USP10 is phosphorylated by ATM (Ataxia telangiectasia mutated) at Thr42 and Ser337. USP10 suppresses tumor cell growth in cells with wild-type p53. Increased USP10 expression in mutant p53 background increases p53 levels and promotes cancer cell proliferation, while downregulation of USP10 inhibits cancer cell growth. USP10 also suppresses ubiquitination of the sirtuin family histone deacetylase SIRT6, leading to protection of SIRT6 from degradation by the proteasome (Lin et al., 2013) . This indirectly leads to decreased transcriptional activity of c-Myc, and inhibition of cancer cell proliferation and tumor formation. USP10 is not exclusively found in the cytoplasm and has indeed been reported to deubiquitinate the histone variant H2A.Z (Draker et al., 2011) . Interestingly, other histone-modifying enzymes, including histone acetyltransferases, the deacetylase SirT1 (Vaziri et al., 2001 ) and the demethylase LSD1 (Huang et al., 2007) , have all been shown to target and modify p53 as well. The autophagy regulator Beclin1 has been reported to control the stability of USP10, and also of USP13 (Liu et al., 2011a) .
USP11 has been identified as an IκBα-associated deubiquitinase capable of deubiquitinating IκBα in vitro . IκBα ubiquitination is required for IκBα degradation and NFκB activation. Knock-down of USP11 expression enhances TNFα-induced IκBα ubiquitination and NF-κB activation. USP11 is therefore important for downregulation of TNFα-mediated NFκB activation by modulating IκBα stability. USP11 is also involved in the regulation of TGFβ signaling by deubiquitinating the type I TGFβ receptor (Al-Salihi et al., 2012) . USP11 interacts with SMAD7 and enhances TGFβ signaling. Finally, the USP11 protein has been found in complexes with the DNA damage repair-associated protein BRCA2 (Schoenfeld et al., 2004 ). BRCA2 does not, however, appear to be a physiologic substrate of USP11 and may instead function as a molecular bridge between USP11 and its substrates.
USP12 deubiquitinates non-activated Notch and is required for the lysosomal degradation of this protein (Moretti et al., 2012) . USP12 down-regulation leads to an increased level of Notch molecules at the cell surface. USP12 (and USP46) also acts as a histone H2A and H2B deubiquitinase that regulates Xenopus development (Joo et al., 2011) .
USP13 is a deubiquitinating enzyme for MITF (microphthalmia-associated transcription factor), the activity of which leads to stabilization and upregulation of MITF protein levels. MITF is a basic helix-loophelix-leucine zipper transcription factor and an important regulator in the development and survival of melanocytes. Amplification of MITF is oncogenic in 10-20% of melanomas (Garraway et al., 2005) and inhibition of MITF induces melanoma cell death regardless of whether the gene is amplified or not (McGill et al., 2002) . Conversely, suppression of USP13 (by siRNA knock-down) leads to a dramatic loss of MITF protein. USP13 has been found to be essential for melanoma growth in animal tumor models and targeting this enzyme may provide a therapeutic opportunity.
USP15 regulates the TGF-β pathway and is believed to be important for the proliferation of glioblastoma cells (Eichhorn et al., 2012) . USP15 binds to the SMAD7-SMAD E3 ligase complex and deubiquitinates and stabilizes the type I TGF-β receptor (TGFβR-I), leading to an enhanced TGF-β signal. High expression of USP15 correlates with high TGF-β activity, and the USP15 gene is found amplified in glioblastoma, breast and ovarian cancer. Glioblastoma patients with increased (N2.5) USP15 copy numbers in their tumors have a shorter overall survival time (Eichhorn et al., 2012) . Depletion of USP15 decreases the oncogenic capacity of patient-derived glioma-initiating cells due to the repression of TGF-β signaling, offering a therapeutic opportunity. USP15 is also a DUB for another set of components of the TGF-β signaling pathway, the receptor-activated SMADs (R-SMADs) (Inui et al., 2011) . USP15 opposes R-SMAD monoubiquitination, preventing promoter recognition. USP15 has been found to be associated with the COP9 signalosome where it has been suggested to show a quality control-type function, prevent improper autoubiquitination of labile ligases (Hetfeld et al., 2005; Wee et al., 2005) .
USP16 (also known as Ubp-M) is phosphorylated at the onset of mitosis by cdc-2/cyclin B complexes (Cai et al., 1999) . USP16 is responsible for deubiquitinating H2A during mitosis. H2A deubiquitination by USP16 is a prerequisite for subsequent phosphorylation of histone H3 on Ser10 and for chromosome segregation during mitosis (Joo et al., 2007) .
USP17 has been shown to have a critical role in cell migration and to be a potential target for anti-metastatic therapy (de la Vega et al., 2011) . Depletion of USP17 blocks chemokine-induced subcellular relocalization of GTPases essential for cell motility (Cdc42, Rac and RhoA). USP17 also negatively regulates the activity of Ras-converting enzyme 1 (RCE1) (Burrows et al., 2009 ). RCE1 cleaves RAS at its C-terminal CAAX motif and expression of USP17 leads to impaired Ras membrane localization and activation.
USP18 is a deubiquitinase of the ISG15 protein (ISG15: interferonstimulated gene 15) (Malakhov et al., 2002) . Mice that are genetically defective in USP18 are hypersensitive to interferon. USP18 was subsequently shown to block the interaction between JAK kinase and the IFN receptor (Malakhova et al., 2006) . All-trans-retinoic acid treatment increases USP18 expression in acute promyelocytic leukemia (APL) cells, leading to stabilization of the PML/RARα protein. USP18 knockdown decreases PML/RARα protein levels and inhibits APL cell proliferation (Guo et al., 2010) .
USP19 has been described to be involved in a number of cellular processes. USP19 is a membrane-anchored DUB localized to the endoplasmic reticulum and a key component of ERAD (endoplasmic-reticulum associated degradation) (Hassink et al., 2009 ). USP19 has been suggested to participate in a late step of the protein quality-control machinery by rescuing ERAD substrates that have been retro-translocated to the cytosol. Interestingly, USP19 contains a co-chaperone-like domain, which may be involved in the proposed rescue process. USP19 also interacts with HIF-1α, promoting its stability and an appropriate hypoxia response (Altun et al., 2012) . USP19 stabilizes the KPC1 ubiquitin ligase, involved in regulation of the p27
Kip1 cyclin-dependent kinase inhibitor (Lu et al., 2009 ). Depletion of USP19 by RNA interference leads to p27 Kip1 accumulation and inhibition of the proliferation of fibroblasts (Lu et al., 2009 ). The ability of USP19 to regulate cell proliferation and p27 Kip1 levels appears to be cell context-dependent, and is lost when fibroblasts are transformed by an oncogenic form of Ras (Lu et al., 2011) . USP19 also interacts with the inhibitors of apoptosis (IAPs) c-IAP1 and c-IAP2 (Mei et al., 2011) . Knockdown of USP19 decreases levels of these c-IAPs, whereas overexpression results in increases in the levels of these apoptosis inhibitors. Knock-down of USP19 enhances TNFα-induced caspase activation and apoptosis in a c-IAP1-and c-IAP2-dependent manner. USP21 was found to be unique among cellular DUBs by showing clear association with centrosomes and microtubules in a GFP-based screen (Urbe et al., 2012) . Binding to microtubules occurs via a novel microtubule-binding motif at the N-terminus of USP21. Depletion of USP21 is required for recovery from microtubule depolymerization and is required for nerve growth factor-induced neurite outgrowth in PC12 cells (Urbe et al., 2012) . USP21 catalyzes the hydrolysis of ubiquitinated H2A (Nakagawa et al., 2008; Okuda et al., 2013) . During chromatin assembly in vitro, ubiquitinated H2A represses di-and trimethylation of H3K4. USP21 relieves this repression and is believed to be associated with de-repression of transcriptional initiation by inhibiting H3K4 methylation.
USP22 was described as one of 11 death-from-cancer signature genes that are critical in controlling cell growth and death (Glinsky, 2006) . USP22 is a positive regulator of the histone deacetylase Sirt1 . USP22-mediated stabilization of Sirt1 leads to decreases in p53 acetylation and suppression of p53 function. In contrast, knock-down of USP22 leads to destabilization of Sirt1, increases in p53 acetylation and induction of p53-dependent apoptosis. USP22 has, similar to USP12 and USP46, been described to deubiquitinate H2A and H2B Joo et al., 2011) .
USP25 is suppressed by miR-200c, leading to inhibition of tumor cell migration and invasion in vitro and inhibition of lung metastasis formation in vivo (Li et al., 2014a ). USP25 protein and mRNA level expression were elevated in non-small cell lung cancer tumors and correlated with clinical stage and lymphatic node metastasis of patients (Li et al., 2014a) . USP25 has been shown to interact with the SYK non-receptor tyrosine kinase (Cholay et al., 2010) and has been implicated in ERAD (Blount et al., 2012) USP28 plays a critical role in regulation of the Chk2-p53-PUMA-signaling pathway, important for DNA-damage-induced apoptosis in response to double-strand breaks (Zhang et al., 2006; Bohgaki et al., 2013) . USP28 is required for stabilization of Chk2 and 53BP1 in response to DNA damage. Upon DNA damage in the G2 phase of the cell cycle, Usp28 protects claspin from APC/CCdh1-mediated degradation. Usp28 permits claspin-mediated activation of Chk1 in response to DNA damage.
The transcription factor MYC is dysregulated in a number of neoplasms, including colorectal tumors (Diefenbacher et al., 2014) and bladder cancers (Guo et al., 2014a) . Similar to other transcription factors such as p53, c-MYC is difficult to target directly using small molecules. Interestingly, USP28 is required for the stability of the MYC oncoprotein in human tumor cells (Fig. 7) (Popov et al., 2007) . USP28 controls MYC stability by counteracting the activity of the SCFFBW7 ubiquitin ligase complex (Popov et al., 2007) . It was recently demonstrated that USP28 antagonizes the ubiquitin-dependent degradation of not only MYC, but also of c-JUN and NOTCH (Diefenbacher et al., 2014) . Mice lacking USP28 showed reduced intestinal cell proliferation and fewer intestinal tumors. Depletion of USP28 reduced tumor size and increased the lifespan of tumor-bearing mice.
The chromatin modulator LSD1 controls cellular pluripotency through histone demethylation and is overexpressed in many tumor types. USP28 has been shown to stabilize LSD1 via deubiquitination (Wu et al., 2013) . Knock-down of USP28 using RNA interference results in destabilization of LSD1 and leads to the suppression of cancer stem cell-like characteristics and inhibition of tumorigenicity in vivo (Wu et al., 2013) . Another function of USP28 is its ability to antagonize the ubiquitin ligase Fbw7, resulting in stabilization of the HIF-1α transcription factor (Flugel et al., 2012) . The inhibition of the enzymatic activity of USP28 may be a potential target for cancer therapy.
USP29 has attracted interest following the finding that the gene encoding this DUB is imprinted and is transcribed mainly from the paternal allele (Kim et al., 2000) . USP29 is involved in the control of the stability of claspin, a protein that has a key role in the ATR-Chk1 branch of the DNA damage checkpoint (Martin et al., 2014) . USP29 knockdown results in an impaired phosphorylation of Chk1 after DNA damage. Claspin is also involved in the process of DNA replication and USP29-depleted cells display defects in S-phase progression (Martin et al., 2014) . In addition, USP29 has been found to be transcriptionally induced following oxidative stress, where it contributes to the full induction of a p53 response (Liu et al., 2011b) .
USP33 (also called VDU1) was originally discovered as a DUB which binds to the pVHL-containing E3 ligase complex targeted for ubiquitin (Ub)-mediated degradation . The USP33 homolog VDU2 is also referred to as USP20. USP33 has been found to be localized to the secretory pathway, and one splice variant accumulates at the Golgi apparatus (Thorne et al., 2011) . Substrates identified so far for USP33 and/or its homolog USP20/VDU2 include the RAS-like GTPase RALB (Simicek et al., 2013) , type 2 iodothyronine deiodinase (D2) (CurcioMorelli et al., 2003) and HIF-1α . Deubiquitylation of RALB by USP33 promotes the assembly of complexes which contain Beclin-1 and which stimulate autophagosome formation (Simicek et al., 2013) . USP33 also binds to the Robo1 receptor and is required for the responsiveness of breast cancer cells to the migration factor Slit (Yuasa-Kawada et al., 2009). USP33 deubiquitinates the CP110 protein, an important regulator of centrosome duplication . Overexpression of CP110 leads to centrosome over-duplication and genomic instability (Chen et al., 2002a) . CP110 levels are controlled through ubiquitination by the SCF ligase complex and through deubiquitination by USP33. During duplication and elongation of centrioles in S and G2/ M phases, USP33 localizes to centrioles. Down-regulation of USP33 destabilizes CP110 and thereby inhibits centrosome amplification and mitotic defects .
USP34 is encoded by a gene region on 2p15-16.1 which is amplified during progression of follicular lymphoma (FL) to diffuse large B-cell lymphoma (DLBCL) (Kwiecinska et al., 2014) . Haploinsufficiency for USP34 appears to affect the regulation of developmental processes (Fannemel et al., 2014) . USP34 has been reported to act downstream of the β-catenin destruction complex in the Wnt pathway (Lui et al., 2011) . Knock-down of USP34 by RNA interference leads to degradation of axin, a scaffolding protein, and to inhibition of β-catenin-mediated transcription. Finally, USP34 has a role in proper maintenance of genome stability due to its role in stabilizing the E3 ligase RNF168, important for assembly of K63-linked chains at DNA double strand breaks (Sy et al., 2013) .
USP42 is a fusion partner in the (7;21)(p22;q22) translocation in acute myeloid leukemia (AML) (Paulsson et al., 2006) . The genomic breakpoint is in intron 7 of RUNX1 and intron 1 of USP42. The RUNX1 transcription factor is a key regulator of hematopoiesis and is involved in numerous translocations in AML (Osato, 2004) . USP42 was subsequently described as an additional deubiquitinating enzyme for p53, similarly to USP2a, USP7 and USP10. USP42 was reported not to affect the basal levels of p53, but to be important during the early phase of a stress response, helping to rapidly induce p53 levels (Hock et al., 2011) .
USP44 is an important regulator of the mitotic spindle checkpoint. USP44 prevents the premature activation of the anaphase-promoting complex (APC), an ubiquitin ligase that promotes sister chromatid separation. This is achieved by stabilizing the APC-inhibitory Mad2-Cdc20 complex (Stegmeier et al., 2007a) . Cells that overexpress Usp44 have been found to be prone to chromosome segregation errors and aneuploidization Zhang et al., 2012) . USP44 has also been shown to be a H2B deubiquitinase (Fuchs et al., 2012) .
USP47 is responsible for deubiquitination the key base excision repair (BER) DNA polymerase (Pol β) (Parsons et al., 2011) . Knockdown of USP47 results in decreased levels of Pol β and a deficiency in BER. Similar to USP30 and USP33, USP47 is involved in the Met receptor tyrosine kinase-activated scattering response of epithelial cells (Buus et al., 2009) . USP47 also interacts with the E3 ubiquitin ligase SCF(betaTrcp) (Skp1/Cul1/F-box protein beta-transducin repeat-containing protein). Depletion of USP47 increases Cdc25A levels in cells and decreases cell survival, suggesting possibilities of therapeutic intervention (Peschiaroli et al., 2010) .
N-Myc Max
USP50 is believed to be involved in repressing entry into mitosis following activation of the DNA damage checkpoint (Aressy et al., 2010) . USP50 accumulates in the nucleus in response to treatment with DNA damaging agents. HSP90 is a major interacting partner for USP50 and depletion of USP50 results a loss in accumulation of the HSP90 client Wee1.
CYLD germline mutations occur in familial cylindromatosis and some other rare autosomal dominant inherited disorders associated with the development of multiple skin tumors of the head and neck (Bignell et al., 2000; Poblete Gutierrez et al., 2002) . Hyperactive Wnt signaling has been demonstrated in CYLD mutant human cylindroma tumors (Tauriello et al., 2010) . The underlying mechanism of activation has been shown to be via enhanced K63-linked ubiquitination of Dvl (Dishevelled), the cytoplasmic effector of Frizzled, in the absence of functional CYLD (Tauriello et al., 2010 ). An important function of CYLD is regulation of NFκB activation (Trompouki et al., 2003) . CYLD inhibits NFκB-mediated activation by different TNF receptor family members due to deubiquitination and inactivation of TNFR-associated factor 2 (TRAF2) and TRAF6. It was later shown that CYLD removes K63-linked polyubiquitin chains from the Bcl-3 protein, resulting in retention of Bcl-3 in the cytoplasm (Massoumi et al., 2006) . Bcl-3 associates with the NFκB p50 or p52 subunits and enhances cell proliferation through activation of the cyclin D1 promoter. In CYLD-deficient keratinocytes, Bcl-3 accumulates in the nucleus, leading to activation of NFkB target genes. CYLD also has another cell-cycle regulatory function, being important for proper regulation of mitotic entry (Stegmeier et al., 2007b) .
UCHL1 was identified as being overexpressed in lung adenocarcinomas using a proteomics approach (Chen et al., 2002b) . UCHL1 overexpression in tumors was associated with patients having a smoking history. Interestingly, UCHL1 was reported to be consistently upregulated in airway epithelial samples obtained from smokers, compared with nonsmokers (Carolan et al., 2006) . Overexpression of UCHL1 was speculated to represent an early event in the transformation process of normal lung epithelium (Carolan et al., 2006) . In contrast to these findings, the UCHL1 gene was found to be silenced in giant cell tumors of bone (Fellenberg et al., 2010) . Silencing was associated with methylation of the CpG island covering the UCHL1 promoter. The UCHL1 gene has also been found to be silenced by methylation in colon cancer cell lines (Fukutomi et al., 2007) .
BAP1 (BRCA1 associated protein-1) is a nuclear-localized DUB of the UCH family originally identified as an interacting partner of the BRCA1 tumor suppressor protein (Jensen et al., 1998 ). BAP1 has not been demonstrated to deubiquitinate BRCA1, but fulfills various criteria of having a tumor suppressor function. Deletions and missense mutations in the BAP1 gene are found in lung and breast tumors and lung cancer cell lines (Buchhagen et al., 1994; Jensen et al., 1998; Jensen & Rauscher, 1999) . The BAP1 protein is also inactivated in a fraction of clear cell renal cell carcinomas (RCC) (Pena-Llopis et al., 2012) and BAP1 inactivating mutations have been demonstrated in~25% of malignant pleural mesotheliomas (Bott et al., 2011) . Cancer-associated BAP1 mutants are deficient in deubiquitinating activity (Ventii et al., 2008) . BAP1 can suppress tumorigenicity of lung cancer cells in athymic nude mice (Ventii et al., 2008) . BAP1 loss sensitizes RCC cells in vitro to genotoxic stress (Pena-Llopis et al., 2012) . BAP1 interacts with the transcriptional cofactor HCF-1 (host cell factor 1). By regulating HCF-1 protein levels, BAP1 may be involved in cell cycle control by associating with genes involved in G1-S transition (Misaghi et al., 2009) .
OTUB enzymes (OTU domain-containing ubiquitin aldehydebinding proteins) constitute a subfamily of 14 DUBs characterized by an ovarian tumor (OTU) domain (Borodovsky et al., 2002; Balakirev et al., 2003) . Ovarian tumor domain DUBs show specificity for different Ub chain linkages. OTUB1 and A20 are specific to K48-linked chains, Cezanne shows specificity to K11-linked chains and TRABID cleaves K29-and K33-linked chains (Eletr & Wilkinson, 2014) .
OTUB1 inhibits UBC13 (also known as UBE2N) and other E2 enzymes. UBC13 heterodimerizes with UEV1A to synthesize K63-linked polyubiquitin chains at double strand breaks in a process also requiring the ubiquitin ligase (E3) RNF168 (Stewart et al., 2009) . OTUB1 directly suppresses MDM2-mediated p53 ubiquitination, and overexpression of OTUB1 leads to stabilization and activation of p53 (Sun et al., 2012) . Monoubiquitination of OTUB1 increases the interaction with UbcH5, resulting in a suppression of UbcH5 activity (Li et al., 2014b) . OTUB1 deubiquitinates estrogen receptor α (ERα) and negatively regulates ERα mediated transcription (Stanisic et al., 2009) . OTUB1, as well as OTUB2, negatively regulates virus-induced type I IFN induction and antiviral responses by deubiquitinating TRAF3 and TRAF6 .
OTUD1 was reported to be highly expressed in thyroid carcinomas and an OTUD1 antibody was able to distinguish carcinomas from benign lesions (Carneiro et al., 2014) .
OTUD4 is a deubiquitinase which appears to be involved in XPC recycling. OTUD4 has been demonstrated to interact with the xeroderma pigmentosum complementation group C (XPC) protein (Lubin et al., 2014) .
OTUD5 (DUBA) is activated by phosphorylation (Huang et al., 2012 ) and suppresses the type I interferon response by cleaving the polyubiquitin chain from tumor necrosis factor receptor-associated factor 3 (TRAF3) (Kayagaki et al., 2007) . In addition, OTUD5 is also a deubiquitinating enzyme for p53 which is required for the stabilization and the activation of a p53 response A20 (TNFα-induced protein 3 (TNFAIP3)) is an important negative regulator of the transcription factor NFκB. A20 inhibits the NFκB pathway by removing the K63-linked polyubiquitin chains on RIP1 (receptor interacting protein 1) (Wertz et al., 2004) and TRAF6 (TNF receptorassociated factor 6) (Ma & Malynn, 2012) (Fig. 8) . The N-terminus of A20 contains an OTU domain whereas the C-terminal portion contains seven zinc finger structures. A20 is considered as an ubiquitin-editing enzyme with both DUB and E3 ligase activity (Ma & Malynn, 2012; Shembade & Harhaj, 2012) . During TNF-mediated stimulation, A20 expression levels increase, leading to deubiquitination of K63-linked chains on the RIP1 protein, but after some hours A20 conjugates K48-linked polyubiquitin chains on the same RIP1 substrate, triggering its degradation by the proteasome. A20 acts as a tumor suppressor in lymphoid malignancies due to its NFκB inhibiting role (reviewed in Harhaj and Dixit (2012) ). As discussed in a previous section, the A20 gene is mutated/deleted in various types of lymphoma (Honma et al., 2009; Novak et al., 2009; Schmitz et al., 2009; Dong et al., 2011; Zhang et al., 2012) . In contrast, forced overexpression of A20 in breast cancer cells leads to tamoxifen resistance (Vendrell et al., 2007) .
Cezanne is an OTU deubiquitinase with sequence homology to A20 (Evans et al., 2003) . Cezanne is induced by TNF-α in cultured cells and silencing of Cezanne leads to elevated NFκB activity in response to this cytokine (Enesa et al., 2008) . It was suggested that miR-218 regulates the ability of TGF-β to induce myofibroblast differentiation via a pathway involving Cezanne (Guo et al., 2014b) .
Ataxin-3 was identified as the protein product of the MachadoJoseph disease gene locus (Kawaguchi et al., 1994) . Machado-Joseph disease is a dominantly inherited form of spinocerebellar ataxia. Ataxin-3 contains a poly-glutamine stretch, the expansion of which is associated with the disease. Additional proteins (ataxin 3-like and Josephin domain containing 1) showing pronounced homology to ataxin-3 were later identified and named Josephins (Albrecht et al., 2003) . Ataxin-3 is a DUB which has been implicated in ERAD and the regulation of autophagy. Ataxin-3 is a poly-glutamine containing deubiquitinating enzyme (DUB) that interacts with the p97 ATPase and with various shuttling factors such as HHR23A and -B (Boeddrich et al., 2006) . Ataxin-3 associates with parkin, HDAC6 (histone deacetylase 6) and other aggresome components . Ataxin-3 trims K63-linked chains from misfolded ubiquitinated proteins and enhances the rate of aggresome formation (Burnett & Pittman, 2005) . Josephin DUBs have roles in cell signaling: all three members are implicated in regulation of PTEN (phosphatase and tensin homolog) expression (Sacco et al., 2014) . Interestingly, DUB-mediated regulation occurs at the level of transcription by an unidentified mechanism. Importantly, knock-down of ataxin-3 using siRNA leads to PTEN induction and downregulation of PI3K signaling.
BRCC36 is a member of the JAMM (JAB1/MPN/MOV34 metalloenzyme) class of DUBs. BBRC36 was isolated as a constituent of an enzyme complex also containing BRCA1, BRCA2, and RAD51 (Dong et al., 2003) . BRCA1 is recruited to DNA double-strand breaks by the ubiquitin-binding protein RAP80 (Sobhian et al., 2007) . The role of BRCC36 in this complex may be to terminate signaling following completion of DNA repair (Shao et al., 2009 ). Cancer-associated BRCA1 mutations decrease the association between BRCC36 and BRCA1 (Dong et al., 2003) . Interestingly, aberrant expression of BRCC36 was observed in breast cancer cell lines and tumors (Dong et al., 2003) . Knock-down of BRCC36 in breast cancer cells leads to sensitization to ionizing radiation (Chen et al., 2006) . This effect was found to be associated with a loss of BRCA1 activation.
Small molecule DUB inhibitors
Similar to protein kinase inhibitors, a span of small molecule DUB inhibitors has been described ranging from broad pan-enzyme inhibitors to specific inhibitors of single DUB enzymes. Also in analogy with kinase inhibitors, unspecific inhibitors are likely to elicit more profound biological effects but also to show stronger unspecific toxicity. Inhibition of multiple DUBs is predicted to induce cellular changes such as (a) increased accumulation of polyubiquitinated proteins/unanchored polyubiquitin chains (if the proteasome/USP5 is inhibited); (b) declines in the pool of monomeric ubiquitin, (c) slower rates of polyubiquitin disassembly, (d) an overall decrease in individual DUB activities, and (e) affect cellular levels/activities of DUB-regulated oncoproteins (discussed by Kapuria et al. (2010)). The subject has recently been reviewed elsewhere Buckley & Crews, 2014) . A number of individual DUBs have been reported to be involved in the control of programmed cell death (apoptosis) (Ramakrishna et al., 2011 ). An example is USP7 inhibition that results in decreased levels of Mdm2, leading to stabilization of p53. Inhibition of multiple DUBs may be expected to amplify these affects (if they regulate essential substrates) but may also be predicted to increase the quantity of polyubiquitinated proteins/unanchored polyubiquitin chains. The inhibition of some DUBs, particularly those associated with the proteasome, can lead to impaired proteasome function and accumulation of misfolded proteins in cells. Such accumulation will lead to proteotoxicity and ultimately cell death.
Synthetic small molecule DUB inhibitors
USP7 (HAUSP) has attracted significant interest from drug developers due to its role in controlling p53 stability. P022077 was identified as a specific USP7 inhibitor by Progenra (Tian et al., 2011) . P5091 is an inhibitor of USP7 and USP47 (Chauhan et al., 2012; Weinstock et al., 2012) and was found to induce apoptosis of multiple myeloma cells resistant to the 20S proteasome inhibitor bortezomib. Specificity was validated using USP7 knockout cells. P5091 was reported to be well tolerated by animals and to inhibit tumor growth (Chauhan et al., 2012) . A more potent analog of P5091 has subsequently been described (cpd 14) (Weinstock et al., 2012) (Table 1) .
USP14 is one of the three distinct DUBs that are associated with proteasomes (RPN11, UCHL5 and USP14). USP14 disassembles proteasome-bound polyubiquitin chains from their distal tips. USP14 activity leads to suppression of substrate degradation by disengaging the substrates from the proteasomes (Lee et al., 2011) . A small molecule inhibitor of USP14 (IU1; Fig. 9 ) has been described which indeed enhances proteasome function in cells (Lee et al., 2010) . This compound binds specifically to the activated, proteasome bound, form of USP14. Increasing proteasomal-mediated degradation by IU1 or similar inhibitors may be of therapeutic benefit in diseases such as Alzheimer's disease (Lee et al., 2010) . The situation appears to be quite complex, however, since USP14 appears to be essential for the maintenance of synaptic ubiquitin levels and the development of neuromuscular junctions (Wilson et al., 2002; Chen et al., 2009) . It is, however, quite possible that loss of USP14 protein does not elicit the same effect on cells as inhibition of enzyme activity. LDN-57444 is an isatin O-acyl oxime reported to selectively inhibit UCHL1 (Liu et al., 2003) . LDN-57444 is a reversible, competitive, and active site-directed inhibitor. The inhibitor increased proliferation of the H1299 lung tumor cell line but had no effect on a lung tumor line that does not express UCHL1 (Liu et al., 2003) . LDN-57444 was found to increase the levels of polyubiquitinated proteins and to induce apoptosis associated with ER stress in SK-N-SH neuroblastoma cells (Tan et al., 2008) .
Pimozide (an anti-psychotic drug) and GW7647 (a PPAR-α agonist) were identified as inhibitors of USP1/UAF1 in a high-throughput screen . These drugs were found to act synergistically with cisplatin in inhibiting proliferation of cisplatin-resistant non-small cell lung cancer cells .
HBX 19,818 is a specific inhibitor of USP7 that covalently modifies the active Cys223 residue of this enzyme (Reverdy et al., 2012) . LS1 is an UCHL3 inhibitor which was identified in a FRET-based screen where fluorescently labeled ubiquitin was attached to substrates containing quenchers (Ohayon et al., 2012) . PR-619 is a general DUB enzyme inhibitor, but does not inhibit other classes of cysteine proteases (Altun et al., 2011) . LDN91946 was identified in an in vitro screen for inhibitors of Ub-AMC activity (Mermerian et al., 2007) . The compound was reported to be a non-competitive inhibitor of UCHL1, but did not inhibit other cysteine proteases such as UCHL3, USP5 and caspase-3.
DUB inhibition by cyclopentone prostaglandins
Fitzpatrick and coworkers (Mullally et al., 2001) originally reported that cyclopentone prostaglandins of the PGJ2 class induce accumulation of polyubiquitinated proteins in cells and inhibit DUB activity. Prostaglandin PGJ2 is a metabolite of PGD2 that is sequentially metabolized to Δ12-PGJ2 or to 15Δ-PGJ2 (Fitzpatrick & Wynalda, 1983) . PGJ2 prostaglandins contain α,β-unsaturated ketones that function as Michael acceptors (Fig. 9) . Cyclopentenone PGs react with thiol molecules at the β-position within the cyclopentenone ring (Suzuki et al., 1997) . The mechanism(s) of UPS inhibition by PGs may be complex. One study reported that a major intracellular target of protein carbonylation was the S6 ATPase of the 26S proteasome. Protein carbonylation and oxidative stress induced by PGs decreased the activities of the S6 ATPase and that of the proteasome (Ishii et al., 2005) . Other investigators have reported that cyclopentone PGs inhibit cellular DUB activities: UCHL3 was found to be inhibited by Δ12-PGJ2 and UCHL1 by 15Δ-PGJ2 (Liu et al., 2011c) . 15Δ-PGJ2 affects UCHL1 overall structure, resulting in inhibition of enzyme activity (Koharudin et al., 2010) . 15Δ-PGJ2 has also been reported to stabilize p53, but p53 function was functionally inactivated by binding of the PG to the Cys-277 residue (Kim et al., 2010) . Cysteine modification sites of 15Δ-PGJ2 have been identified in UCHL1 (Koharudin et al., 2010) and in Ras (Renedo et al., 2007) . Cyclopentenone PGs are known to induce apoptosis by mechanisms that do not require the p53 pathway (Mullally et al., 2001 ). Oxidative stress induced by 15Δ-PGJ2 was reported to be associated with the formation of adducts between PG and thioredoxin 1 (Shibata et al., 2003) . Two cysteine residues in thioredoxin 1, Cys-35 and Cys-69, were found to be modified by 15Δ-PGJ2. Interestingly, UCHL1 was reported to be among the proteins that were oxidized in cells exposed to 15Δ-PGJ2 (Ishii & Uchida, 2004) (Table 2) .
The DUB inhibitory activity of cyclopentone PGs is very likely due to the presence of Michael acceptors in these compounds and the fact that the vast majority of DUBs are cysteine proteases. Among the amino acid residues in proteins, cysteine is the most nucleophilic and reactive. Whereas the pK a of free cysteine is 8.4, the pK a of a cysteine residue in a protein is affected by the environment and varies between 4 and 9. Basic residues close to cysteine sulfhydryls in the protein structure decrease the pK a of cysteine and result in ionization to cysteine thiolate (RS−) at neutral pH. The nucleophilic nature of cysteine thiolate allows it to react with Michael acceptors such as those present in maleimides, vinyl sulfones, acrylamides, and α,β-unsaturated ketones and aldehydes. (Colombo et al., 2010; Byun et al., 2013) IU1 USP14 (Lee et al., 2010 ) Isatin O-acyl oxime derivatives UCHL1 (Liu et al., 2003) LDN91946 UCHL1 (Mermerian et al., 2007 ) LS1 UCHL3 (Ohayon et al., 2012 ) NSC112200, NSC267309
TRABID/ZRANB1 (Shi et al., 2012) PR-619 Broad spectrum DUB inhibition Electrophiles differ with regard to their degree of reactivity to nucleophiles based on the "hard/soft" acid-base principle (Lopachin et al., 2012) . α,β-Unsaturated ketones are considered as relatively soft electrophiles and believed to be selective in their reaction to a subset of cysteine thiolates in proteins . Proteomic studies have shown that electrophiles react with "hyper-reactive" cysteines in proteins (Weerapana et al., 2010; Codreanu et al., 2014) . Acrolein (an α,β-unsaturated aldehyde), glyoxal (a dialdehyde) and various keto- Ataxin-3 aldehydes are more reactive and cytotoxic compared to α,β-unsaturated ketones . Acrolein reacts with guanine bases in DNA, and with cysteine, lysine, histidine, and arginine residues. Punaglandins, chlorinated cyclopentenone PGs, are more potent inhibitors of cellular DUB activity than the J-series PGs (Verbitski et al., 2004) . The increased inhibitor activity was speculated to be due increased reactivity towards the nucleophilic addition of the DUB catalytic cysteine thiol group (Verbitski et al., 2004) .
Chalcone DUB inhibitors
A chalcone is an aromatic ketone and an enone that forms the central core for a variety of important biological compounds. A number of chalcone compounds (e.g. G5, b-AP15, RA-9) have been described to inhibit cellular deubiquitinase activity (Fig. 9) . These compounds are unrelated to PGs, but contain cross-conjugated α,β-unsaturated ketones and accessible β-carbons, and generally inhibit DUB activity. These compounds have been reported to be either relatively specific (b-AP15) or broad spectrum (G5) DUB inhibitors. The reasons for these apparent discrepancies are unknown.
Compounds G5 and F6 were identified in a cell based screen for Bcl-2-independent apoptosis (Aleo et al., 2006) . Both compounds are chalcones that contain cross-conjugated α,β-unsaturated ketones. These compounds were reported to inhibit total DUB activity (Aleo et al., 2006) and F6 was reported to inhibit USP2 and USP7 and also the SENP2 deSUMOylase (Nicholson et al., 2008) . G5 induces apoptosis at concentrations of~1 μM, and necrotic cell death at higher concentrations (10 μM) (Fontanini et al., 2009 ).
b-AP15 (Fig. 9 ) was identified in cell based screens for compounds inducing apoptosis independently of p53 and cathepsin-D (Erdal et al., 2005; Berndtsson et al., 2009 ) and was found to induce the accumulation of polyubiquitin in cells (Berndtsson et al., 2009) . Subsequent work showed that this compound blocks degradation of a proteasomedegraded reporter protein, suggesting that DUB inhibition was linked to a decrease in proteasome function (D'Arcy et al., 2011) . b-AP15 inhibits the activity of proteasome associated cysteine DUBs (USP14 and UCHL5) at concentrations of~5 μM (D' Arcy et al., 2011; Wang et al., unpublished data) (Fig. 10) . Dual inhibition of USP14 and UCHL5 using RNA interference is known to lead to strong accumulation of proteasomal substrates and loss of cell viability (Koulich et al., 2008; Tian et al., 2013; Wang et al., 2014) . Surprisingly, b-AP15 did not inhibit total cellular DUB activity at concentrations of 20-50 μM (D'Arcy et al., 2011) . Considering the structural similarity between b-AP15 and other chalcones, these differences in specificity are surprising and are as of yet unexplained (see further below). b-AP15 shows considerable anti-neoplastic activity in animal models, both against solid tumors (D'Arcy et al., 2011) and against multiple myeloma (Tian et al., 2013) . The cytotoxic activity of the drug is strongly associated with functional proteasome inhibition. Thus, monitoring accumulation of a proteasome-degraded reporter (Ub G76V -YFP) in cells exposed to low concentrations of b-AP15 showed a very strong correlation between blocking of proteasome activity and cell death (Brnjic et al., 2013; Wang et al., 2014) . Importantly, examination of the cellular response to b-AP15 using gene expression profiling and CMAP analysis (Lamb et al., 2006) showed that this compound induced a very similar change in gene expression as a number of proteasome inhibitors and to 15Δ-PGJ2 (D'Arcy et al., 2011) .
AM146, RA-9, RA-14 and RAMB1 are all chalcones (RA-9 shown in Fig. 9 ) (Anchoori et al., 2011; Issaenko & Amerik, 2012) . These compounds were described to act as partially selective DUB inhibitors and to induce rapid accumulation of polyubiquitinated proteins and to deplete the cellular pools of free ubiquitin. AM146, RA-9, and RA-14 were found to inhibit UCHL1, UCHL3, USP2 and USP8, but did not suppress the activity of Ataxin-3, A20, BAP1, Otubain 1 or USP7 (Issaenko & Amerik, 2012) . These compounds elicit apoptosis of breast, ovarian and cervical cancer cells but not of primary human cells. Fig. 9 ) is a small-molecule compound that inhibits several DUBs of both USP and UCH subclasses, including USP9x, USP5, USP14 and UCHL5 (Kapuria et al., 2010) . In cells, the inhibition of DUB activity resulted in the accumulation of polyubiquitinated conjugates. WP1130 induces the accumulation of free polyubiquitin chains, presumably due to inhibition of USP5 (isopeptidase-T). Downregulation of the anti-apoptotic protein MCL1 was observed in cells exposed to WP1130. This effect is expected from the inhibition of USP9x, and is not observed in cells exposed to b-AP15 (X.W., unpublished observation). Pham and colleagues showed that WP1130 in combination with bortezomib had antitumor activity in a mantle cell lymphoma animal model (Pham et al., 2010) . In distinction to b-AP15, WP1130 was reported not to induce oxidative stress (Kapuria et al., 2010) . The inhibition of USP14 and UCHL5 by WP1130 is expected to induce a functional block of proteasome function in cells, but this has not been tested.
Other DUB inhibitors containing Michael acceptors
Eeyarestatin-1 (Eer1) (Fig. 9 ) was identified in a screen for inhibitors of the ERAD pathway (Fiebiger et al., 2004) . Subsequent studies have shown that Eer1 inhibits p97/VCP-associated DUB activity, and that ataxin-3 activity is inhibited by this compound . Using surface plasmon resonance and pull-down assays, Eer1 has been shown to directly bind to the p97 ATPase (261). Eer1 appears to have complex mechanisms of action in the ER compartment since the compound also inhibits anterograde translocation of proteins over the ER (Cross et al., 2009; Aletrari et al., 2011) . Eer1 has anti-cancer activities resembling those of bortezomib (Wang et al., 2009 ).
Natural products with DUB inhibitory activity
A number of compounds have been described in the literature to affect the UPS without direct inhibition of proteasome activity. Some of these compounds have been reported to be DUB inhibitors.
Curcumin is a yellow pigment from the herb Curcuma longa present in the Indian spice turmeric (associated with curry powder). Curcumin is one of the most studied phytochemicals; in August 2014 a PubMed search for "curcumin" and "cancer" resulted in 2579 hits (reviewed in Shishodia et al. (2005) ). Curcumin has been linked with suppression of tumorigenesis as well as a number of other pathological conditions and has been shown to be extremely safe even at very high doses. Curcumin is a homodimer of feruloylmethane containing a methoxy group and a hydroxyl group (Fig. 9) . Importantly, curcumine contains two α,β-unsaturated ketone moieties which are important for its anticancer activity. Using a shotgun proteomic approach, it was found that curcumin induces the accumulation of polyubiquitinated proteins at concentrations of 40 μM (D' Aguanno et al., 2012) . The ability of curcumin to modulate molecular targets relevant to cancer, such as NFκB, cyclin D1 and p21, may be speculated to be secondary to inhibition of the UPS (Shishodia et al., 2005) (Table 3) .
The 4-arylidene curcumin analog AC17 (Fig. 9 ) has been shown to inhibit the deubiquitinase activity of the 19S RP (Zhou et al., 2013) (Fig. 10) . AC17 inhibits NFκB activity and activates p53 in human lung cancer cells and has anti-tumor activity in an in vivo model of human lung cancer. AC17 was reported to be an irreversible inhibitor of 19S DUB activity, presumably USP14/UCHL5 (Zhou et al., 2013) . AC17 does not inhibit total DUB activity in cell lysates (Zhou et al., 2013) .
Betulinic acid is triterpene that has been isolated from many diverse plants, including the birch tree, Betula. Betulinic acid is cytotoxic against a range of cancer cell lines, and shows significant in vivo activity in human melanoma xenograft animal models (Pisha et al., 1995) . A 20% betulinic acid ointment has been evaluated in the treatment of dysplastic nevi (http://www.cancer.gov/drugdictionary?CdrID=496932). Betulinic acid was recently reported to be a broad spectrum DUB inhibitor (Reiner et al., 2013) . Betulinic acid has previously been used as a reagent in cancer research based on its ability to induce loss of transmembrane potential in isolated mitochondria and to induce apoptosis (Fulda et al., 1998) .
Gambogic acid (GA) is a cytotoxic compound isolated from gamboge, a brownish resin of the tree Garcinia hanburyi in Southeast Asia. This plant product has been used in Chinese traditional medicine for centuries (Zhang et al., 2004; Chen et al., 2008) . GA has been shown to be an anticancer drug candidate with documented cytotoxic activity in several types of cancer cells (Wu et al., 2004b; Reutrakul et al., 2007; Yi et al., 2008) . The Chinese Food and Drug Administration has approved a phase II clinical trial of GA as an antitumor candidate . GA has an α,β-unsaturated ketone structure which is essential for growth inhibition and apoptosis induction in cancer cell lines (Fig. 9) (Zhang et al., 2004; Reutrakul et al., 2007) . The gene signature observed in cells exposed to GA is similar to that of cells exposed to UPS inhibitors such as PGJ2, celastrol and withaferin A (Felth et al., 2013) . As expected from this result, GA induces the accumulation of polyubiquitinated proteins. The presence of α,β-unsaturated ketones suggested that GA may inhibit cellular DUB activity, and this was indeed found to be the case (Felth et al., 2013) . The compound also inhibits 20S proteasome activity (Felth et al., 2013) .
Specificity of inhibitors containing α,β-unsaturated ketones
Michael acceptor-based inhibitors will achieve maximal selectivity by targeting poorly conserved, noncatalytic cysteines (Singh et al., 2011) . Inhibitors with Michael acceptors that are believed to target catalytic cysteines in DUBs nevertheless appear to show considerable specificity. Some inhibitors such as b-AP15 and AC17 were reported to show specificity to proteasomal DUBs (D'Arcy et al., 2011; Zhou et al., 2013) , whereas others such as WP1130 showed a larger range of activities but nevertheless some specificity (Kapuria et al., 2010) . Some of these differences may reflect different binding to target DUBs due to 3-D conformation of the inhibitors. However, it is surprising that G5/F6 is broad specificity DUB inhibitors and b-AP15 is specific to proteasomal DUBs, considering the similar molecular structures (i.e. chalcone) of these drugs. b-AP15 has a low solubility in aqueous buffers, and it is conceivable that b-AP15 would inhibit non-proteasomal DUBs if soluble at 10-50 μM. However, analysis of myeloma cells exposed to 1 μM b-AP15 showed inhibition of USP14 in the same protein extracts where USP7, UCHL3 or UCHL5 was not inhibited (Tian et al., 2013) . Considering the expected cytotoxicity resulting from blocking of proteasome function, we believe it to be likely that the inhibition of proteasomal DUBs (USP14/UCHL5) is of key importance to the biological effects of chalcones and other α,β-unsaturated ketone-containing compounds.
Compounds containing α,β-unsaturated ketones frequently induce cellular oxidative stress (Raj et al., 2011; Adams et al., 2012) . Such compounds have also been proposed to directly react with proteins, creating "electrophilic stress" (Adams et al., 2012) . Cyclopentone PGs, curcumin and b-AP15 have all been found to inhibit thioredoxin reductase (Moos et al., 2003; Fang et al., 2005; Wang et al., 2014) and 15Δ-PGJ2 binds two cysteines in thioredoxin (Shibata et al., 2003) . In the instance of b-AP15, various pieces of evidence suggested that thioredoxin reductase inhibition contributes to oxidative stress by this compound but does not appear essential for cytotoxicity (Wang et al., 2014) . Induction of an oxidative stress response is a general feature of proteasome inhibitors (including bortezomib and MG-262 (Ling et al., 2003; Wu et al., 2002) ), and may not necessarily require specific molecular sensors such as Keap1-Nrf2 (Gao et al., 2007) . When compared side-by-side, b-AP15 and the thioredoxin reductase inhibitor auranofin induce similar levels of oxidative stress, but only b-AP15 induces proteasome inhibition (Wang et al., 2014) .
Cysteine-dependent enzymes are not necessarily inhibited by α,β-unsaturated ketone-containing compounds. Neither glutathione reductase nor caspase-3, enzymes which both contain cysteines in their active sites, are inhibited by b-AP15 (Wang et al., 2014 ) (X.W., unpublished information). PGJ2 induces a decline in proteasome activity and a shift in the molecular make-up of proteasomes (decreases in 26S particles and increases in 20S core particles) . b-AP15 does not inhibit proteasome activity (D'Arcy et al., 2011) and does not affect the assembly of proteasomes in cells (M. Mazurkiewicz, unpublished data). 15Δ-PGJ2 has also been shown to covalently bind to a cysteine residue in the PPARγ ligand (Shiraki et al., 2005) and to bind actin and other Table 3 Natural products which are candidate DUB inhibitors.
Compound
Reported activity Curcumin Accumulation of polyubiquitin, contains α,β unsaturated ketones (Mullally and Fitzpatrick, 2002; D'Aguanno et al., 2012 ) AC17 (curcumin analog) USP14, UCH-L5 (Zhou et al., 2013) 
Betulinic acid
Broad spectrum DUB inhibition (Reiner et al., 2013) 
Gambogic acid
Accumulation of polyubiquitin, contains α, β unsaturated ketones (Felth et al., 2013) abundant cellular proteins (Aldini et al., 2007) . Morphologic changes in the actin filament network were observed using high concentrations (20 μM) of 15Δ-PGJ2 (Aldini et al., 2007) . Exposure of cells to 15Δ-PGJ2 does not induce major shifts in the position of proteins found to react with the PG on two-dimensional gels (Aldini et al., 2007) , suggesting that only a minor fraction of the protein was covalently modified. With regard to the reactivity of dienones, see further below. It is difficult to deduce the molecular mechanism of action of 15Δ-PGJ2, b-AP15 and other compounds using proteomic data since identified targets are not necessarily associated with induction of apoptosis. However, using CMAP analysis of induced gene expression profiles, 15Δ-PGJ2 and b-AP15 show profiles which are similar (but not identical) to those of 20S proteasome inhibitors (D'Arcy et al., 2011).
Pharmacological properties of compounds containing α,β-unsaturated ketones
Curcumin is safe to humans at doses of 12 g/day but exhibits poor bioavailability (Anand et al., 2007) . Low plasma/tissue levels appear to be mainly due to poor absorption and rapid metabolism. The antitumor effects observed with orally administered curcumin in some studies are somewhat surprising considering the limited bioavailability of this compound. The use of piperine, an agent that interferes with glucuronidation, has been reported to increase bioavailability (Shoba et al., 1998; Anand et al., 2007) .
An intriguing property of some of the inhibitors discussed here is their stronger inhibitory effect in cellular assays compared to biochemical in vitro assays. b-AP15 blocks proteasome activity in cellular assays (accumulation of polyubiquitin and proteasome-degraded reporters) in the 0.1-0.5 μM range, but inhibits proteasomal DUB activity in vitro at a concentration of~10 μM (Wang et al., 2014) . This compound was found to be rapidly taken up and enriched in cells (Wang et al., 2014) , explaining this apparent inconsistency. Enrichment appears to be thiol-driven (Wang et al., 2014) . Eer1 shows in vitro activity at 70 μM in biochemical assays whereas 8 μM Eer1 is sufficient to block translocation of proteins over the ER in cultured cells (Cross et al., 2009 ). This discrepancy was suggested to result from metabolism of Eer1 in vivo . Cyclopentenone PGs have been found to be enriched in cells by a factor of~20-fold (Narumiya & Fukushima, 1986) . Cellular enrichment of cyclopentenone PGs was reported to be due to active transport over cell membranes (Narumiya & Fukushima, 1986) .
Reactivity of α,β-dienones present in DUB inhibitors
Cysteine residues are ideal targets for covalent drugs with the potential of target specificity and a prolonged residence time and, hence, duration of action (Serafimova et al., 2012) . The BTK inhibitor ibrutinib and the EGFR inhibitor afatinib represent examples of covalent kinase inhibitors that target noncatalytic cysteine thiols Schwartz et al., 2014) . Irreversible Michael acceptors such as acrylamides may be converted to electrophiles that react with cysteine thiols in a rapidly reversible fashion (Serafimova et al., 2012) . We have found that the b-AP15 inhibitor induces reversible inhibition of proteasome-associated DUB activity both in vitro (enzyme assays using 26S proteasomes) or in vivo (determining the levels of polyubiquitin after removal of drug) (D'Arcy et al., 2011; Wang et al., 2014) . Issaenko and Amerik (2012) reported that the chalcone AM146 elicited an irreversible commitment for cell death, suggesting that the compound is an irreversible inhibitor. Whether DUB activity was irreversibly inhibited was not tested, however, and it is possible that commitment to cell death was achieved even after short exposures to AM146, as found using b-AP15 (Wang et al., 2014) .
Addition of thiols such as glutathione to dienone PGs occurs more rapidly but results in more labile thiol conjugates compared to enone PGs (Suzuki et al., 1997) . Interestingly, dienone reactivity is considered to be under kinetic control whereas enone reactivity is under thermodynamic control. Cross-conjugated dienone PGs undergo reversible Michael addition reactions with glutathione, generating an equilibrium mixture shifted to the free PG over the conjugated PG (Suzuki et al., 1997) . In contrast, enone PGs bind glutathione in an irreversible manner so the equilibrium favors thiol conjugate formation. CDDO (2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid) is a semi-synthetic triterpenoid which contains two α,β-unsaturated carbonyls and is a promising chemopreventive and chemotherapeutic agent. CDDO has been demonstrated to react with thiol nucleophiles, but nucleophilic addition is both selective and reversible (Couch et al., 2005) .
The pattern of reactivity of compounds containing α,β-unsaturated carbonyls can be fine-tuned by manipulating their electronic properties (Amslinger, 2010) . Some of the differences in the specificity by these compounds with regard to DUB inhibition could be envisioned to be due to the varying strength of the electrophiles. Another important issue is the potential general reactivity of these compounds, which would seriously compromise the bioavailability of the drugs by nonselective addition to scavengers such as glutathione, and could also be envisioned to lead to general toxicity. However, most of the evidence in the literature suggests that nucleophile addition to dienones is reversible and that a major fraction of various compounds are free to bind various intracellular targets. It may nevertheless be advantageous to attempt to develop prodrugs where the α,β-unsaturated carbonyl reactivity is activated in intracellular compartments.
Conclusions
Great efforts have been made to develop inhibitors of targets in the UPS other than the proteasome. So far, however, no compounds have been approved for clinical use. The potential to influence processes such as signal transduction, proliferation and apoptosis by affecting ubiquitination and proteasomal degradation of key regulators is both promising and exciting. DUBs are likely to be more druggable than E3 ligases owing to the lack of defined catalytic residues in the latter. Most DUBs are cysteine enzymes which should be easy to drug, particularly using compounds containing Michael acceptors. The degree of specificity which can be achieved by such compounds is uncertain. The overall importance of DUBs for central cellular processes such as proper proteasomal function may explain the cytotoxic profiles of interesting natural products such as curcumin and synthetic chalcones. Bioavailability is a hurdle that needs to be overcome, but if progress can be made in this area molecules containing functional dienones as well as other types of compounds may be developed into useful cancer therapeutics.
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